Brooks Laboratories (BROOKS) | Stock Overview & Key Data
Brooks Laboratories Performance Comparison
Stock Range
Today's Range
Low: ₹143.60
High: ₹146.88
on August 22, 2025
52 Week Range
Low: ₹95.55
High: ₹198.86
on February 28, 2025
on January 7, 2025
All-Time High: ₹198.86 on January 6, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR4.3B
EPS
0.47
P/E Ratio (TTM)
310.21
Forward P/E
25.09
P/B Ratio
4.01
PEG Ratio
25.09
Div. Yield
N/A
ROE
-10.16%
Beta
0.710
Debt to Equity
7.73
Financial Highlights
Profitability
Gross Margin
32.19%
Operating Margin
10.72%
Profit Margin
2.25%
Returns and Earnings
Return on Assets (TTM)
-8.06%
Return on Equity (TTM)
-10.16%
EBITDA
INR78.2M
Net Income (TTM)
INR20.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR30.60
Quarterly Revenue Growth (YoY)
42.30%
Quarterly Earnings Growth (YoY)
35.19%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Brooks Laboratories BROOKS | 4.32B Small-cap | -3.85% | -10.63% | 7.01% | 20.53% | -21.44% | 3.25% | 16.03% | 270.10% |
| Sun Pharmaceutical SUNPHARMA | 3.95T Large-cap | 0.56% | -2.16% | -4.47% | 0.14% | -13.13% | -7.54% | 86.54% | 195.42% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -0.21% | -6.98% | -5.91% | 7.87% | 1.29% | 26.68% | 71.47% | 87.96% |
| Sun Pharma Advanced SPARC | 47.41B Small-cap | 1.72% | -7.23% | -10.11% | 14.74% | -27.21% | -34.43% | -37.13% | -23.18% |
| Aarti Drugs AARTIDRUGS | 42.99B Small-cap | -4.13% | -10.00% | 1.76% | 27.10% | 6.05% | -14.34% | 10.27% | -34.08% |
| Sequent Scientific SEQUENT | 44.38B Small-cap | 0.12% | -6.92% | -2.35% | 12.64% | -4.77% | 5.41% | 52.52% | 30.60% |
Ownership & Short Interest
Insider Ownership
55.28%
Institutional Ownership
9.90%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
23K
Average 90-Day Volume
20K
Brooks Laboratories Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Brooks Laboratories would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BROOKS's 52-week high and low?
- In the last 52 weeks, Brooks Laboratories reached a high of ₹198.86 (on January 7, 2025) and a low of ₹95.55 (on February 28, 2025).
- What is the market cap and P/E ratio for BROOKS?
- Curious about Brooks Laboratories's size and valuation? Its market capitalization stands at 4.32B. When it comes to valuation, the P/E ratio (trailing twelve months) is 310.21, and the forward P/E (looking ahead) is 25.09.
- Does BROOKS pay dividends? If so, what's the yield?
- As for dividends, Brooks Laboratories isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Brooks Laboratories's main competitors or similar companies to consider before investing?
When looking at Brooks Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.95T Healthcare Drug Manufacturers - Specialty & Generic -7.54% 86.54% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 26.68% 71.47% Sun Pharma Advanced
SPARC47.41B Healthcare Drug Manufacturers - Specialty & Generic -34.43% -37.13% Aarti Drugs
AARTIDRUGS42.99B Healthcare Drug Manufacturers - Specialty & Generic -14.34% 10.27% Sequent Scientific
SEQUENT44.38B Healthcare Drug Manufacturers - Specialty & Generic 5.41% 52.52% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Brooks Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Brooks Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -10.16%, the Debt to Equity ratio from the most recent quarter is 7.73, and its Gross Profit Margin stands at 32.19%.
- What is the recent revenue and earnings growth for BROOKS?
- Looking at Brooks Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR901M. Compared to the same quarter last year (YoY), quarterly revenue grew by 42.30%, and quarterly earnings saw a YoY growth of 35.19%.
- How much of BROOKS stock is held by insiders and institutions?
- Wondering who owns Brooks Laboratories stock? Company insiders (like executives and directors) hold about 55.28% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 9.90%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.